Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML

International Journal of Hematology

Volumn 102, Issue 5, 2015, Pages 553-557

  Jeziskova, Ivana ^a,b   Musilova, Milena ^b   Culen, Martin ^b   Foltankova, Veronika ^a,b   Dvorakova, Dana ^a,b   Mayer, Jiri ^a,b   Racil, Zdenek ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

AML preleukemic stem cells; DNMT3A gene mutations; MRD; Next generation sequencing

Indexed keywords

CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; CODON; DNA (CYTOSINE 5) METHYLTRANSFERASE; TUMOR MARKER; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; INTERMEDIATE RISK POPULATION; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; TREATMENT DURATION; ACUTE MYELOID LEUKEMIA; AMINO ACID SUBSTITUTION; GENETICS; PHYSIOLOGIC MONITORING;

ADULT; AGED; AMINO ACID SUBSTITUTION; BIOMARKERS, TUMOR; CODON; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUTATION, MISSENSE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL;

EID: 84947032179     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1856-3     Document Type: Article

References (12)

1. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179–98.
2. Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119:559–68.
3. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.
4. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30:742–50.
5. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29:2889–96.
6. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.
7. Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H, et al. The interlaboratory robustness of next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25:1840–8.
8. Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol. 2014;167:478–86.
9. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
10. Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548–53.
11. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
12. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.